Tianjin Third Central Hospital

Running trials

• Not yet recruiting

  AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer

  NCT07712094· Phase 2· Source

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Source

• Not yet recruiting

  Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer

  NCT07007286· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Active, not recruiting

  Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

  NCT06174402· Phase 2/3· Source

• Recruiting

  Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

  NCT05862337· Phase 3· Source

• Recruiting

  Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

  NCT05749822· Phase 2/3· Source

• Enrolling by invitation

  A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  NCT06707922· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Active, not recruiting

  A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

  NCT04344158· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Hepatitis B2 recruiting
• Liver and biliary tract cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

  NCT06544551· Phase 3· Source

• Completed

  A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

  NCT04948697· Phase 2· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source

• Completed

  A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  NCT04846491· Phase 3· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Source

Trial sites

• Third Central Hospital of Tianjin1 trial
• Tianjin Third Central Hospital17 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Hepatitis B10 works · 4 trials